Key result
Elevated plasma IL-15 is linked to ~32% higher risk of acute myocardial infarction.
Why the study?
While interleukin-15 (IL-15) has been implicated in immune regulation, its precise role in the pathogenesis of acute myocardial infarction has not been clarified.
Does IL-15 deletion or inhibition improve myocardial recovery and reduce inflammation following acute myocardial infarction?
Case-Control (n=243)
Does IL-15 deletion or inhibition improve myocardial recovery and reduce inflammation following acute myocardial infarction?
IL-15 exacerbates cardiac ischemic injury by impairing macrophage efferocytosis and promoting inflammation, suggesting it may be a therapeutic target for myocardial recovery post-AMI.
Answers are grounded in this paper and cite their sources.
IL-15 may worsen AMI injury via macrophage dysfunction; hypothesis-generating in animal models, clinical trials needed.
Acute myocardial infarction (AMI) remains a major global health burden and is characterized by profound cardiac inflammation, apoptotic cell death, and impaired myocardial function. While interleukin-15 (IL-15) has been implicated in immune regulation, its precise role in the pathogenesis of AMI has not been clarified. Therefore, this study sought to delineate the functional role of IL-15 in the progression of AMI, with a particular focus on its influence on macrophage-driven inflammation, efferocytosis, and metabolic reprogramming. IL-15 levels were assessed in AMI patients and murine models. To evaluate the impact of IL-15 on cardiac inflammation, apoptosis, and functional outcomes following AMI, IL-15 and IL-15 receptor α ( IL-15Rα ) knockout (KO) mouse models were employed. Mechanistic studies were conducted to investigate IL-15-mediated effects on macrophage efferocytosis, polarization, and metabolic remodeling, with an emphasis on nuclear factor-κB (NF-κB) signaling and glycolytic flux. Elevated IL-15 levels were detected in both the plasma of AMI patients and the cardiac tissues of murine AMI models, correlating with increased disease severity. The genetic deletion of IL-15 or IL-15Rα significantly ameliorated cardiac injury by reducing inflammation and apoptosis while preserving myocardial function. Mechanistic analyses revealed that IL-15 impaired macrophage efferocytosis via Mer tyrosine kinase (MERTK) downregulation and promoted M1 polarization via NF-κB pathway activation. Furthermore, IL-15 reprogrammed macrophage metabolism by enhancing glycolytic activity. Ultimately, IL-15 restoration exacerbated cardiac ischemic injury following AMI, serving as a critical regulator of macrophage-mediated inflammation in AMI. These findings highlight the role of IL-15 as a potential therapeutic and prognostic target for mitigating cardiac inflammation and improving myocardial recovery in AMI.
No takes yet. Share an insight, caveat, or question.
Guo et al. (2026) conducted a case-control in Acute myocardial infarction (n=243). Elevated IL-15 levels vs. Non-CAD controls was evaluated on Acute myocardial infarction (aOR 1.320, 95% CI 1.130-1.542, p=<0.001). Elevated plasma IL-15 levels were associated with an increased risk of acute myocardial infarction.
Synapse has enriched 10 related papers. Consider them for comparative context: